Hiroyuki Okuzawa, Director, Executive Officer, Head of Corporate Planning & Management Div., CFO Wataru Takasaki, Executive Officer, Head of R&D Div. PLAY LIST from the beginning FY2021 Q1 Financial Results Presentation Forward-Looking Statements 1. FY2021 Q1 Financial Results Overview of FY2021 Q1 Results Revenue Core Operating Profit Profit Attributable to Owners of the Company Revenue: Business Units (incl. Forex Impact) Revenue: Major Products in Japan 2. Business Update ENHERTU(R): Revenue ENHERTU(R): Performance in Each Region Japan:New Product Approval 3. R&D Update 3ADCs update ENHERTU(R):Breast cancer ENHERTU(R):Gastric cancer ENHERTU(R):NSCLC,CRC Dato‐DXd:Breast cancer,NSCLC HER3‐DXd: NSCLC Alpha update DS‐5670 (COVID‐19 mRNA vaccine) DS‐3201 (EZH1/2 inhibitor):Presented interim results of NHL Ph1 study at EHA DS‐3201 Ph1: Efficacy results DS‐3201 Ph1:Most Common TEAEs DS‐3201 ATL/PTCL development plan Other Alpha update WCLC/ESMO 2021 Planned Presentation at WCLC/ESMO 2021 News Flow FY2021 News Flow 4. Appendix Major R&D Milestones in FY2021 (3ADCs) Major R&D Milestones in FY2021 (Alpha) Major R&D Pipeline: 3ADCs Major R&D Pipeline: Alpha @ Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Q&A 7 Back Next